Public comment periods — page 5
120 consultations carrying 1,332 signed submissions. Every submission has a declared interest, a secretariat response and a disposition.
Consultations
-
Consultation on the draft of this methodological review, which registers the question: For neuropeptides holding a national marketing registration outside the jurisdictions the Institute routinely reviews, what evidence is retrievable and…
16 submissions1 not accepted -
Consultation on the draft monograph for Survodutide, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at moderate certainty and states the basis for…
14 submissions3 not accepted -
Consultation on the draft of CEI-MS-10, which specifies the performance a determination must achieve for content and states what the resulting figure does not establish. The draft states performance rather than prescribing a fixed…
16 submissions1 not accepted -
Consultation on the draft of this intervention review, which registers the question: In adults with obesity and moderate to severe obstructive sleep apnoea, what is the effect of a pharmacological weight-reducing agent on the…
16 submissions1 not accepted -
Consultation on the draft monograph for Thymosin alpha-1, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at moderate certainty and states the basis…
13 submissions2 not accepted -
Consultation on the policy governing how the Institute cites evidence. The draft requires that every citation resolve to a retrievable source, that an identifier the Institute does not hold be recorded as not held rather than…
9 submissions2 not accepted -
Consultation on the draft monograph for Larazotide acetate, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at moderate certainty and states the…
8 submissions1 not accepted -
Consultation on the draft monograph for AOD-9604, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at very low certainty and states the basis for…
17 submissions2 not accepted -
Consultation on the draft of this methodological review, which registers the question: What is known about the direction and magnitude of the difference between sponsor-conducted and independently conducted trials, and how should an…
10 submissions2 not accepted -
Consultation on the draft of this network meta-analysis, which registers the question: Does an oral presentation of a glucagon-like peptide-1 receptor agonist achieve an efficacy and tolerability profile comparable with an injectable…
15 submissions1 not accepted -
Consultation on the draft monograph for Gonadorelin, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at moderate certainty and states the basis for…
9 submissions -
Consultation on the draft of this intervention review, which registers the question: What is the effect of an amylin receptor agonist alone and in combination with a glucagon-like peptide-1 receptor agonist on body weight?
9 submissions1 not accepted -
Consultation on the policy governing how the Institute corrects a published document and how versions are numbered, retained and linked. The draft retains every superseded version at a stable address and requires that a correction state…
19 submissions2 not accepted -
Consultation on the draft monograph for Hexarelin, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at very low certainty and states the basis for…
7 submissions -
Consultation on the draft of this analytical evidence review, which registers the question: How large is the discrepancy between labelled peptide mass and delivered peptide mass when counter-ion and water content are not reported?
16 submissions1 not accepted -
Consultation on the draft monograph for Kisspeptin-10, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at low certainty and states the basis for…
4 submissions -
Consultation on the policy governing the public register of Institute members, reviewers, correspondents and contributors: who appears, what is published about each, and what is not. The draft publishes affiliation and declared interests…
13 submissions2 not accepted -
Consultation on the draft monograph for IGF-1 LR3, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at very low certainty and states the basis for…
9 submissions -
Consultation on the second version of the framework the Institute uses to rate certainty in a body of evidence. The revision retains the four-level GRADE scale and alters the way the two lowest ratings are explained, after the assessment…
15 submissions2 not accepted -
Consultation on the draft monograph for LL-37, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at low certainty and states the basis for that rating…
6 submissions
page 5 of 6